1,721,137 research outputs found

    Electronic cigarettes for smoking cessation

    Get PDF
    Supplementary data tables of results drawn from included studies

    Electronic cigarettes for smoking cessation: April 2021

    Get PDF
    We included 56 completed studies, representing 12,804 participants, of which 29 were RCTs. Six of the 56 included studies were new to this review update. Of the included studies, we rated five (all contributing to our main comparisons) at low risk of bias overall, 42 at high risk overall (including the 25 non-randomized studies), and the remainder at unclear risk. There was moderate-certainty evidence, limited by imprecision, that quit rates were higher in people randomized to nicotine EC than in those randomized to nicotine replacement therapy (NRT) (risk ratio (RR) 1.69, 95% confidence interval (CI) 1.25 to 2.27; I2 = 0%; 3 studies, 1498 participants). In absolute terms, this might translate to an additional four successful quitters per 100 (95% CI 2 to 8). There was low-certainty evidence (limited by very serious imprecision) that the rate of occurrence of AEs was similar) (RR 0.98, 95% CI 0.80 to 1.19; I2 = 0%; 2 studies, 485 participants). SAEs occurred rarely, with no evidence that their frequency differed between nicotine EC and NRT, but very serious imprecision led to low certainty in this finding (RR 1.37, 95% CI 0.77 to 2.41: I2 = n/a; 2 studies, 727 participants). There was moderate-certainty evidence, again limited by imprecision, that quit rates were higher in people randomized to nicotine EC than to non-nicotine EC (RR 1.70, 95% CI 1.03 to 2.81; I2 = 0%; 4 studies, 1057 participants). In absolute terms, this might again lead to an additional four successful quitters per 100 (95% CI 0 to 11). These trials mainly used older EC with relatively low nicotine delivery. There was moderate-certainty evidence of no difference in the rate of AEs between these groups (RR 1.01, 95% CI 0.91 to 1.11; I2 = 0%; 3 studies, 601 participants). There was insufficient evidence to determine whether rates of SAEs differed between groups, due to very serious imprecision (RR 0.60, 95% CI 0.15 to 2.44; I2 = n/a; 4 studies, 494 participants). Compared to behavioral support only/no support, quit rates were higher for participants randomized to nicotine EC (RR 2.70, 95% CI 1.39 to 5.26; I2 = 0%; 5 studies, 2561 participants). In absolute terms this represents an increase of seven per 100 (95% CI 2 to 17). However, this finding was of very low certainty, due to issues with imprecision and risk of bias. There was no evidence that the rate of SAEs differed, but some evidence that non-serious AEs were more common in people randomized to nicotine EC (AEs: RR 1.22, 95% CI 1.12 to 1.32; I2 = 41%; 4 studies, 765 participants; SAEs: RR 1.17, 95% CI 0.33 to 4.09; I2 = 5%; 6 studies, 1011 participants). Data from non-randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation, headache, cough, and nausea, which tended to dissipate with continued use. Very few studies reported data on other outcomes or comparisons and hence evidence for these is limited, with confidence intervals often encompassing clinically significant harm and benefit

    Cochrane review of electronic cigarettes for smoking cessation (10.1002/14651858.CD010216.pub9)

    No full text
    Supplementary tables 1-10 for the update to the Cochrane review of electronic cigarettes for smoking cessation. Once accepted the DOI for the publication will be: 10.1002/14651858.CD010216.pub

    Electronic cigarettes for smoking cessation: September 2021

    Get PDF
    We included 61 completed studies, representing 16,759 participants, of which 34 were RCTs. Five of the 61 included studies were new to this review update. Of the included studies, we rated seven (all contributing to our main comparisons) at low risk of bias overall, 42 at high risk overall (including all non-randomized studies), and the remainder at unclear risk. There was moderate-certainty evidence, limited by imprecision, that quit rates were higher in people randomized to nicotine EC than in those randomized to nicotine replacement therapy(NRT) (risk ratio (RR) 1.53, 95% confidence interval (CI) 1.21 to 1.93; I = 0%; 4 studies, 1924participants). In absolute terms, this might translate to an additional three quitters per 100 (95%CI 1 to 6). There was low-certainty evidence (limited by very serious imprecision) that the rate of occurrence of AEs was similar (RR 0.98, 95% CI 0.80 to 1.19; I = 0%; 2 studies, 485participants). SAEs were rare, but there was insufficient evidence to determine whether rates differed between groups due to very serious imprecision (RR 1.30, 95% CI 0.89 to 1.90: I = 0;4 studies, 1424 participants). There was moderate-certainty evidence, again limited by imprecision, that quit rates were higher in people randomized to nicotine EC than to non-nicotine EC (RR 1.94, 95% CI 1.21 to3.13; I = 0%; 5 studies, 1447 participants). In absolute terms, this might lead to an additional seven quitters per 100 (95% CI 2 to 16). There was moderate-certainty evidence of no difference in the rate of AEs between these groups (RR 1.01, 95% CI 0.91 to 1.11; I = 0%; 3studies, 601 participants). There was insufficient evidence to determine whether rates of SAEs differed between groups, due to very serious imprecision (RR 1.06, 95% CI 0.47 to 2.38; I = 0;5 studies, 792 participants). Compared to behavioural support only/no support, quit rates were higher for participants randomized to nicotine EC (RR 2.61, 95% CI 1.44 to 4.74; I = 0%; 6 studies, 2886participants). In absolute terms this represents an additional six quitters per 100 (95% CI 2 to15). However, this finding was of very low certainty, due to issues with imprecision and risk ofbias. There was some evidence that non-serious AEs were more common in peoplerandomized to nicotine EC (RR 1.22, 95% CI 1.12 to 1.32; I = 41%, low certainty; 4 studies,765 participants), and again, insufficient evidence to determine whether rates of SAEs differed between groups (RR 1.51, 95% CI 0.70 to 3.24; I = 0%; 7 studies, 1303 participants). Data from non-randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation, headache, cough, and nausea, which tended to dissipate with continued use. Very few studies reported data on other outcomes or comparisons, hence evidence for these is limited, with CIs often encompassing clinically significant harm and benefit

    Oxford Food and Activity Behaviours Study

    Get PDF
    Data from a prospective, web-based cohort study of overweight UK adults (BMIâ¥25kg/m2) trying to lose weight through behaviour change. Strategy use was assessed using the OxFAB questionnaire

    Behavioural interventions for smoking cessation: an overview and network meta-analysis

    Get PDF
    Supplementary tables in Microsoft Word and Excel that provide additional information to accompany the Cochrane Overview: Behavioural interventions for smoking cessation: an overview and network meta-analysi

    Planetary health-informed health systems change: a circumpolar-based multi-methods approach

    Get PDF
    Health systems are underprepared for the effects of an increasingly stressed planet. In this dissertation, I used a multi-methods, pragmatist approach to identify influences on planetary health-informed health systems change in a Circumpolar and diverse healthcare setting, and to explore transferable knowledge for other contexts. Through a mixed-methods systemic review, I identified factors that influence adaptation of patient-planetary health (P-PH) co-benefit prescribing using content analysis. Barriers included a lack of knowledge and time; facilitators included policy statements and guidelines from respected associations. Informed by this review, I then conducted interviews exploring physician perspectives around P-PH co-benefit prescribing in a Circumpolar region. Using reflexive thematic analysis, I found the current healthcare system does not support planetary health, with many physicians discussing difficulties. I then held a sharing circle with Indigenous Elders from the same area, and inductively coded the data to generate key themes and a systems map. Findings included four interconnected themes: the past and how we got here; where we are now; where we need to go in the future; and reflections. Overall, health systems were viewed as devoid of any environmental context or consideration. I then carried out reflexive thematic analysis regarding nature prescriptions in the context of Indigenous Peoples. Findings included the need for things to be done “in the right way”, and the sentiment that the Land is not just an experience but a way of life. Lastly, I carried out a scoping review to identify current planetary health frameworks for health systems. Using content analysis to identify the different domains, I described six overarching categories including, as examples: key structural components for environmentally sustainable health systems; climate resilient and sustainable technologies and infrastructure; and evaluation and accountability mechanisms. By triangulating data across these studies, I identified common elements, including an implicit focus and understanding that some level of the status quo (i.e., Nature disconnection) is still being perpetuated within research and discourse around planetary health-related health systems change
    corecore